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for Huntington’s Disease
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SUE LURIE
School of Public Health, University of North Texas Health Science Center, Fort Worth,
Texas, USA
The aim of this literature review was to determine if there is ad-
equate ethical justification for presymptomatic genetic testing on
potential Huntington’s disease patients. Huntington’s disease is a
neurological genetic disorder characterized by midlife onset which
consists of cognitive, physical, and emotional deterioration. Al-
though genetic testing has traditionally been guided by the prin-
ciple of autonomy, severe psychological consequences such as de-
pression, anxiety, survival guilt, and suicide have complicated the
ethical issue of providing a presymptomatic yet definitive diagnosis
for an incurable disease. An analysis of available articles yielded
inconclusive findings, namely due to insufficient evidence, self-
selection bias of test participants, or lack of a longitudinal design.
Additional results indicated psychological distress is not solely as-
sociated with test result, but rather with individual characteristics
including, but not limited to, psychological history, test motivation,
level of preparation, social support, and age. In the interest of up-
holding the principles of autonomy, beneficence, nonmaleficence,
and justice, it is recommended that medical professionals follow
strict protocol, provide extensive counseling, and employ vigilance
when assessing at-risk individuals for HD presymptomatic test eli-
gibility to ensure psychological well-being.
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Huntington’s Disease (HD), also called Huntington’s chorea, was first docu-
mented in 1872 by American physician George Huntington (Skirton, 2005).
HD causes deterioration of cognitive, physical, and emotional abilities lead-
ing to serious incapacitation and eventual death some 15 to 20 years after
the onset of symptoms (Bombard et al., 2007). The cognitive symptoms of
HD include difficulties with problem solving and planning, impaired short-
term memory, and ultimately dementia; physical symptoms include jerky
involuntary movements called chorea, slurred speech, difficulty swallow-
ing, and abnormal walking; and emotional symptoms consist of depression,
mood changes, aggression, and impulsiveness (Dawson, Krisitijanson, Toye,
& Flett, 2004). The most common age of onset for HD is between 30 and
45 years old, with symptoms usually beginning around 40 years old, yet
symptoms can start as early as childhood or as late as the eighth decade
of life (Keenan, Miedzybrodzka, Van Teijlingen, Mckee, & Simpson, 2007;
Timman, Bonke, Stijjnen, Tibben, & Maat-Kievit, 2008). It is one of the most
devastating diseases, not only because of its constant degenerative deterio-
ration, but also because of the emotional and psychological impact it has on
individuals and their families (Dawson et al., 2004).
Individuals suffering from HD have a mutant gene IT-15 on the short
arm of chromosome four, which codes for the protein huntingtin (Htt) (van
Duijn, Kingma, & van der Mast, 2007). Specifically, the affected allele con-
tains repeats of 36 or more of the CAG trinucleotide, whereas unaffected
individuals have 35 or less (Walker, 2007). While the exact mechanism of
the disease is not fully understood, it has been proposed that the polyglu-
tamine tail caused by the CAG repeats aggregate and impede the function of
other proteins, neuronal signaling, and the cells’ ability to break down the
huntingtin, thereby producing symptoms of the disease (Walker, 2007).
As of 2008, there were an estimated 30,000 cases of HD in the United
States, with about 150,000 individuals at risk of inheriting HD from a parent
(National Center for Biotechnology Information, 2008). Children who have
a parent with HD genetically have a 50% risk of developing the disease
(Skirton, 2005). HD is not gender specific, it affects both genders equally, and
if a child inherits the huntingtin-mutated gene, he/she will eventually develop
the disease (Cox & Mckellin, 1999). Individuals cannot be a carrier without
developing the disease and it does not skip generations (Dawson et al., 2004).
Currently, there are no available treatments to reverse or stop the pro-
gression of HD, however, presymptomatic genetic testing has been available
since 1993 (Pakenham, Goodwin, & Macmillan, 2004). Individuals who are
aware of the disease being present in their family may choose to have
presymptomatic testing to determine their mutation status before they show
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Ethics of Genetic Testing for Huntington’s Disease 131
onset of symptoms (Hamilton, Bowers, & Williams, 2005). There are benefits
of presymptomatic testing, which include relief of uncertainty, knowing the
potential risk for offspring, and ability to plan for the future. There are also
psychological risks that can follow presymptomatic testing, including anxi-
ety, depression, stress, guilt, and thoughts of suicide (Soldan, Street, Gray,
Binedell, & Harper, 2000). HD falls into a category that has a highly valid
genetic test but no effective treatment, producing concerns related to poten-
tial discrimination and psychological distress (Burke, Pinsky, & Press, 2001).
This implies an ethical dilemma in balancing the risks of testing as contrasted
with potential benefits.
Whether analyzing HD or any other illness, treatment alternatives always
involve ethical principles commonly identified by various health care ethics
experts (Beauchamp & Childress, 2001). Normally four ethical principles
are used as moral measures: autonomy, beneficence, nonmaleficence, and
justice (Hursthouse, 2003).
• Autonomy
The word autonomy refers to the ability to decide for one’s self. Autonomy
as a concept means that the person is self-ruling, free to make his or
her own decisions. In a health care setting, it is often unclear whether
the patient possesses the conditions for autonomy or not. Two impor-
tant conditions must be met for autonomy: competence and noncoercion
(American Medical Association, 2001).
• Beneficence
Beneficence means to do well and to provide a benefit. It is the practice of
doing a kindness or good thing and implies more than just avoiding doing
harm. This ethical principle of having to engage in altruistic or beneficent
acts means that one is obligated to take proactive and direct steps to help
others (Morrison, 2006).
• Nonmaleficence
Nonmaleficence means to not do wrong toward another. Medical ethicists
and physician educators have long established the dictum of, first, do no
harm. This is not an easy rule to follow due to the debate concerning the
meaning of the word harm. It is no simple matter because much of health
care involves pain, discomfort, inconvenience, expense, and perhaps even
disfigurement and disability (Summers, 1989). Harm could mean physical
failure, emotional distress, and/or financial loss. Furthermore, harm might
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132 A. Coustasse et al.
also be negligence, lack of due diligence, or violations of patient autonomy
(Betancourt, Green, & Carillo, 2002).
• Justice
Justice is more than just fairness. It also includes elements of righteousness,
equity, and lawfulness. A just person is fair, lawful, reasonable, correct,
and honest. In general, to know something is just is to have a good
reason to think that it is morally correct and proper. The term is often
used to mean fairness in treatment; it is both procedural and distributive.
Procedural justice is defined as due process and being equal under the
law. Distributive justice involves determining how to divide up burdens
and benefits (Arthur & Shaw, 1979).
The purpose of the following research study was to ascertain if there is
clinical support for presymptomatic genetic testing on potential Huntington’s
disease patients in light of ethical considerations.
METHODS
The research was conducted to complete a comprehensive literature review
on the psychological and ethical implications of genetic testing for HD. The
research strategy was limited to selecting articles from reputable journals in
which online access was available from electronic databases. All researched
topics were related to psychological and ethical implications of presymp-
tomatic genetic testing of HD in the potentially affected populations. The
research strategy yielded journal articles of high impact and an analysis of
findings from the literature was performed. The studies were investigated to
determine their pertinent findings and ethical conclusion, whether stated or
implied by the article’s general perspective.
Search Strategy
When completing the online research, the following terms were combined
using the Boolean “OR”: Huntington’s disease, Huntington’s chorea, pre-
symptomatic testing, and ethics. All pertinent articles came from four elec-
tronic databases: EbscoHost, Psyc-Info, Springer, and PubMed. Reference
lists from retrieved articles were utilized to identify other relevant research
articles.
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Ethics of Genetic Testing for Huntington’s Disease 133
Inclusion, Exclusion, and Assessment
There was abundant information available regarding the disease; however,
the review was restricted to literature including information about the psy-
chological and ethical effects of presymptomatic genetic testing in HD. Re-
views and primary research articles were included in this study. All selected
articles were in English. No articles were excluded due to the age of the
article, but unpublished works were excluded from this study.
RESULTS
After reviewing research information available from the electronic databases,
20 specific articles were selected for an analysis in this study. Numerous
articles covering topics in HD such as biological genetic research, geneal-
ogy of the disease, medical and nursing care, and palliative treatment did
not address the research criteria and were excluded from this review. The
20 selected studies included an array of relevant national and international
research. Table 1 illustrates the key issues, findings, and viewpoints related
to the psychological and ethical implications of HD testing.
DISCUSSION
In general, earlier published articles speculated on the ethical principles of
HD testing, yet more recent articles were found to examine the psycholog-
ical effects associated with testing. The passage of time has allowed more
researchers to shift their focus from a hypothetical ethical issue to one based
on clinical evidence and long-term analysis. This shift of focus highlights
the medical community’s desire to describe the fundamental principles of
medical ethics as they realistically apply to HD testing.
Overall, five studies indicated HD testing was ethical and advantageous
to at-risk individuals. However, the validity of these findings could be ques-
tioned due to the impact of inherent biases related to self-selection and
participants’ state of denial (Meiser & Dunn, 2000; Robins Wahlin, 2007).
Furthermore, many of the 20 researchers could not indicate the long-term
effects of their findings due to the lack of a longitudinal design. Longitu-
dinal studies were completed by Tibben, Duivenvoorden, Niermeijer, Van
Der Vlis, Roos, and Verghage (1994), Williams, Schutte, Evers, and Holkup
(2000), Almqvist, Brinkman, Hayden, Wiggins, and the Canadian Collabora-
tive Study of Predictive Testing (2003), and Decruyenaere, Evers-Kiebooms,
Cloostermans, et al. (2003). These studies did show a unique progression
of psychological effects over a period of several years, with most negative
effects decreasing in the long term. However, individual characteristics such
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as mental health status and level of preparation were shown to have as much
of, if not more than, an effect on study participants’ well-being as actual test
results.
The majority of the research reveals that solutions to the ethical dilemma
surrounding HD testing are both inconclusive and multifaceted. While the
decision to be tested has historically been viewed as strictly autonomic, cer-
tain findings indicate a need for intervention for those deemed unprepared
to handle the test implications, based on factors such as psychological history
or test motivation. Huggins, Bloch, Kanani, Quarrell, and Theilman (1990)
addressed the predicament of unanimously adhering to the principles of
autonomy, beneficence, nonmaleficence, and justice when they often con-
tradict each other with respect to HD testing. With no real medical benefit
of knowing one’s fate with respect to HD, autonomy has been given prece-
dence. It is unclear under what exact circumstances a medical professional’s
duty to do what is right and to do no harm can override the autonomous
rights of the individual. Most of the findings uncovered in this study suggest
the principles must be weighed on a case-by-case basis due to the effects of
a great many variables. From the early stages of research to present research,
studies have stressed the important role that strict protocol, pretest assess-
ments, long-term psychological counseling, and social support play in every
case of HD genetic testing. It will be a steep challenge for future researchers
to definitively prove the advantages and disadvantages of presymptomatic
genetic testing over the lifespan, and to complete clear recommendations
on whether or not an at-risk individual should be tested depending on the
known outcomes.
Many researchers pointed out the importance of using HD genetic test-
ing for presymptomatic individuals only, but not as a diagnostic tool for
those who have already developed the disease. For presymptomatic indi-
viduals, the test outcome can give them a sense of control over their lives,
allow them to plan for their future, and provide assistance with making
responsible reproductive decisions (Chapman, 2002). Yet the issue is com-
plicated by the somewhat ambiguous nature of the term presymptomatic and
the progressive nature of the disease. The criteria for diagnosis are typically
based on the physical symptoms, yet numerous patients demonstrate cog-
nitive or behavioral changes, including difficulty in concentrating, memory
lapse, and mood swings, prior to the movement disorder onset (Aubeeluck
& Buchaman, 2007).
Further research is needed to determine why so many potential HD
carriers are not getting tested. A survey in 2004 found that approximately 66%
to 79% of individuals who were at risk for Huntington’s disease could have
the presymptomatic genetic testing completed, while research has shown
that only 5% to 15% of those have actually been tested (Pakenham et al.,
2004). Binedell and Soldan (1997) indicated these individuals chose not to
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be tested due to their lack of coping ability, yet insufficient information or
other factors may also contribute.
Other avenues of research continue to emerge that could signifi-
cantly affect the current views on HD genetic testing. Of particular interest
is the clinical research surrounding potential treatment for the cognitive,
psychiatric, or neurological symptoms of HD through use of surgeries
or various medications, including tetrabenazine (Adam & Jankovic, 2008;
Kenney, Hunter, Davidson, & Jankovic, 2007). Obviously, any further ad-
vances and opportunities for what was once thought to be an incur-
able and untreatable disease would alter the fundamentals of the ethical
dilemma.
CONCLUSION
Despite being thoroughly analyzed for nearly two decades, there remains no
definitive consensus on the ethical viability of HD presymptomatic testing.
Many studies pertaining to the issue result in inconclusive findings, namely
due to the inability to accurately measure the positive effects related to re-
productive planning, life planning, and relief of uncertainty against negative
effects experienced through pre- and post-testing for both carriers and non-
carriers of the Huntington’s gene.
Medical professionals and at-risk individuals should take a serious look
at their options and scientific recommendations regarding testing in order to
preserve the best mental health possible for all affected parties. Even though
a significant amount of helpful information was found reflecting the psy-
chological implications of HD presymptomatic testing, further longitudinal
studies should be conducted in order to better understand the long-term
effects. Since there is currently no cure or reliable treatment for Huntington’s
disease, these psychological implications of presymptomatic testing are the
primary criteria for judging whether HD testing maintains the medical ethical
principles of autonomy, beneficence, nonmaleficence, and justice.
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